GP
CLVS

GLG Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

GLG Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$128K Sell
1,886
-347
-16% -$24.3K 0.01% 403
2017
Q3 		$184K Buy
+2,233
New +$177K 0.01% 309
2015
Q4 		– Sell
-38,410
Closed -$3.53M – 538
2015
Q3 		$3.53M Buy
38,410
+3,410
+10% +$295K 0.09% 220
2015
Q2 		$3.08M Buy
+35,000
New +$3M 0.08% 248
2015
Q1 		– Sell
-28,931
Closed -$1.62M – 468
2014
Q4 		$1.62M Sell
28,931
-709
-2% -$37.3K 0.05% 269
2014
Q3 		$1.34M Buy
+29,640
New +$1.24M 0.03% 327

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return